San Diego biotech lands $120M to launch a slate of trials in neurosensory disorders

Days after adding some finance, dealmaking and technical talent to the top team, Escient Pharma has taken the wraps off a $120 million round to go broader in the clinic.

New Enterprise Associates, Abingworth and Forge Life Science Partners co-led the Series C.